Arnaud Pigneux

Click to increase image sizeClick to decrease image size AknowledgementsWe would like to thank all the physicians who are implicated in this family follow-up, including, Pr David Laharie, Dr Thomas Bachelet, Dr Antoine Soulage, Dr Alain Schiano, Dr Isabelle Hamy-Marthan and Dr Marc Simon. We would like to thank Dr David Lawrence for his assistance in English writing.Disclosure statementNo potential conflict of interest was reported by the author(s).

10.1080/10428194.2022.2148377

Cite

Citations (0)

Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia

eJHaem (2024)

Céline Row Nicolas Lechevalier Jean Vial Aguirre Mimoun Jean Bastié

Risk stratification and treatment response evaluation are key features in acute myeloid leukemia (AML) management. Immunophenotypic and molecular approaches all rely on the detection of persisting leukemic cells by measurable residual disease techniques. A new approach is proposed here by assessing medullary myeloid maturation by flow cytometry through a myeloid progenitor ratio (MPR). The normal MPR range was defined using reference normal bone marrows (

Log-rank test

Minimal Residual Disease

NPM1

10.1002/jha2.822

Cite

Citations (1)

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients

Bone Marrow Transplantation (2001)

Olivier Fitoussi Virginie Perreau JM Boiron Emmanuelle Bouzigon Pascale Cony‐Makhoul

Mobilization

Nitrogen mustard

10.1038/sj.bmt.1702879

Cite

Citations (87)

Supplementary Data from Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations

Daniel A. Pollyea Courtney D. DiNardo Martha Arellano Arnaud Pigneux Walter Fiedler

Supplementary Data from Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations

Venetoclax

Azacitidine

10.1158/1078-0432.22486290

Cite

Citations (1)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia

Cancers (2021)

Jean Vial Nicolas Lechevalier Francis Lacombe Pierre‐Yves Dumas Audrey Bidet

The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients while multiparameter flow cytometry (MFC) is more broadly available. However, MFC analysis strategies are highly operator-dependent. Recently, new tools have been designed for unsupervised MFC analysis, segregating cell-clusters with the same immunophenotypic characteristics. Here, the Flow-Self-Organizing-Maps (FlowSOM) tool was applied to assess MFC-MRD in 96 bone marrow (BM) follow-up (FU) time-points from 40 AML patients with available mMRD. A reference FlowSOM display was built from 19 healthy/normal BM samples (NBM), then simultaneously compared to the patient's diagnosis and FU samples at each time-point. MRD clusters were characterized individually in terms of cell numbers and immunophenotype. This strategy disclosed subclones with varying immunophenotype within single diagnosis and FU samples including populations absent from NBM. Detectable MRD was as low as 0.09% in MFC and 0.051% for mMRD. The concordance between mMRD and MFC-MRD was 80.2%. MFC yielded 85% specificity and 69% sensitivity compared to mMRD. Unsupervised MFC is shown here to allow for an easy and robust assessment of MRD, applicable also to AML patients without molecular markers.

Minimal Residual Disease

Identification

10.3390/cancers13040629

Cite

Citations (28)

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Blood (2020)

Amina Cherait Thorsten Braun Krimo Bouabdallah Denis Caillot Agnès Guerci

Azacitidine

Chemotherapy regimen

10.1182/blood-2020-137012

Cite